Nocion: Targeting pain neurons and nothing else

How Nocion is taking the numbness and paralysis out of sodium channel blockers

With a $27 million series A co-led by Canaan and F-Prime Capital announced Wednesday, Nocion thinks it could replace opioids in a range of tissue-localized indications, starting with cough. The company is aiming to minimize the side effects of commonly used analgesics by developing compounds that only affect the cells sensing pain.

Nocion is developing positively charged versions of “caines” -- broadly acting intracellular sodium channel blockers -- that selectively enter the neurons that transmit pain and itch

Read the full 789 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE